St Davids

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved pulsed field ablation system

Retrieved on: 
Tuesday, April 9, 2024
Electrophysiology, St Davids, Atrial fibrillation, Arrhythmia, Patient, PFA, Medical Center, Quality of life, FDA, Food, Medical device

The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.

Key Points: 
  • The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.
  • Dr. Natale and Dr. Al-Ahmad were two of 67 global operators to participate in the trial that led to FDA approval.
  • The novel PFA system delivers short-duration, high-energy electrical pulses to the cardiac tissue to destroy cells that cause irregular heart rhythms without using excess heat or cold.
  • "Our team is honored to have played a part in piloting this new era of global innovation for cardiac arrhythmia."

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved pulsed field ablation system

Retrieved on: 
Tuesday, April 9, 2024
Electrophysiology, St Davids, Atrial fibrillation, Arrhythmia, Patient, PFA, Medical Center, Quality of life, FDA, Food, Medical device

The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.

Key Points: 
  • The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.
  • Dr. Natale and Dr. Al-Ahmad were two of 67 global operators to participate in the trial that led to FDA approval.
  • The novel PFA system delivers short-duration, high-energy electrical pulses to the cardiac tissue to destroy cells that cause irregular heart rhythms without using excess heat or cold.
  • "Our team is honored to have played a part in piloting this new era of global innovation for cardiac arrhythmia."

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
Tuesday, March 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
Tuesday, March 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

Medtronic creates history with FDA approval of its novel PulseSelect™ Pulsed Field Ablation System to treat atrial fibrillation

Retrieved on: 
Wednesday, December 13, 2023
St Davids, Research, Safety, NYSE, Cryoablation, Medical Center, Chosen-ciphertext attack, Medtronic, Patient, PVI, European, FDA, CE, Atrial fibrillation, PFA, Cryo, MD, Diagnosis, Phrenic nerve, Learning curve, Catheter, Electrode, EP, SVP, Cosmetics, Medical device

DUBLIN, Dec. 13, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF). This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November.

Key Points: 
  • This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November.
  • "Launching the first FDA-approved PFA technology is not just a milestone; the PulseSelect PFA system is setting a new standard in safety for AF ablation with excellent efficacy and efficiency1.
  • The learning curve in using the catheter and system is short, and the catheter enables the operator to deliver fast and controlled pulsed field energy for AF ablation."
  • The PulseSelect PFA system also includes the following:
    Designed as a plug-and-play system, PulseSelect can be used with any mapping system or with just fluoroscopy2.

Sendero Health Plans Names Sharon Alvis as Next Chief Executive

Retrieved on: 
Thursday, September 21, 2023
Insurance, EAP, Health, Central Health, Saint David, PHO, PPO, Central Health (Texas), HMO, Preferred provider organization, Health maintenance organization, Organization, Medicare, Hospital, Affordable Care Act, Hugh Delargy, ACA, Physician, National Hospital Organization Nagara Medical Center, Provisions of the Affordable Care Act, Alvis, St Davids, Health insurance marketplace, Curative, Health insurance, Retail, Central Texas

AUSTIN, Texas, Sept. 21, 2023 /PRNewswire/ -- Sendero Health Plans Inc. (Sendero) announced Wednesday it has named Sharon J. Alvis as the new chief executive officer to lead the nonprofit health maintenance organization (HMO), which was created and is funded and owned by Central Health.

Key Points: 
  • AUSTIN, Texas, Sept. 21, 2023 /PRNewswire/ -- Sendero Health Plans Inc. (Sendero) announced Wednesday it has named Sharon J. Alvis as the new chief executive officer to lead the nonprofit health maintenance organization (HMO), which was created and is funded and owned by Central Health.
  • Sendero offers health insurance plans through the Affordable Care Act's (ACA) federal Health Insurance Marketplace.
  • I have closely followed the evolution and experience of Sendero Health Plans from its inception and was excited about the potential to directly contribute."
  • Alvis continued, "With its unique structure and ownership, Sendero, in collaboration with the Central Health System, has a unique opportunity to maximize powerful collective resources.

CUREXO INC.'S ROBOTIC GAIT TRAINING SYSTEM, MORNING WALK S200, INSTALLED IN FIRST US INPATIENT REHABILITATION FACILITY

Retrieved on: 
Wednesday, March 29, 2023
Partnership, Saint David, Stroke, Rehabilitation, Mr and Mrs William Hallett, Patient, Medical Center, Rehabilitation hospital, Virtual reality, FDA, Morning Walk, Injury, Hospital, St Davids

AUSTIN, Texas, March 29, 2023 /PRNewswire/ -- In continuing its strategic partnership with Curexo, Inc. announced last year, Harmonic Bionics has completed the first installation of Curexo's Morning Walk S200 at an inpatient rehabilitation facility in the US.

Key Points: 
  • AUSTIN, Texas, March 29, 2023 /PRNewswire/ -- In continuing its strategic partnership with Curexo, Inc. announced last year, Harmonic Bionics has completed the first installation of Curexo's Morning Walk S200 at an inpatient rehabilitation facility in the US.
  • The Morning Walk S200 is an FDA-registered robotic gait rehabilitation system with a virtual reality component that uses a saddle for weight support and individual foot plates to facilitate more natural walking patterns.
  • St. David's Rehabilitation Hospital, which is located at St. David's Medical Center in Austin, TX, is the first inpatient rehabilitation facility in the US to offer gait training with Morning Walk for patients.
  • The hospital's 64-bed rehabilitation facility provides comprehensive inpatient and outpatient care for patients with neurological conditions, including stroke and orthopedic illnesses or injuries.

Texas Cardiac Arrhythmia Institute physician led international workshop on cardiac arrhythmias

Retrieved on: 
Wednesday, October 26, 2022
Physician, Municipality, VeniceArrhythmias, HRS, Saint David, Cardiac electrophysiology, Electrophysiology, International Scientific Association for Probiotics and Prebiotics, European Society of Cardiology, European Heart Rhythm Association score of atrial fibrillation, Industry, Heart Rhythm Society, Association, St Davids, Arrhythmia, Medical Center, Medical device

AUSTIN, Texas, Oct. 26, 2022 /PRNewswire/ -- The executive medical director of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently led Venice Arrhythmias 2022, a biennial international workshop on cardiac arrhythmias held in Venice, Italy from October 13 to October 15, 2022.

Key Points: 
  • AUSTIN, Texas, Oct. 26, 2022 /PRNewswire/ -- The executive medical director of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently led Venice Arrhythmias 2022, a biennial international workshop on cardiac arrhythmias held in Venice, Italy from October 13 to October 15, 2022.
  • As Venice Arrhythmias president, Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C.,organized the programming for the event.
  • The workshop featured worldwide recognized leaders in the field of basic and clinical cardiac electrophysiology presenting the latest scientific advances and innovations.
  • Venice Arrhythmias wasestablishedin 1989, making it the longest-running and most successful electrophysiology conference in the world.

Texas Cardiac Arrhythmia Institute physician led international workshop on cardiac arrhythmias

Retrieved on: 
Wednesday, October 26, 2022
Physician, Municipality, VeniceArrhythmias, HRS, Saint David, Cardiac electrophysiology, Electrophysiology, International Scientific Association for Probiotics and Prebiotics, European Society of Cardiology, European Heart Rhythm Association score of atrial fibrillation, Industry, Heart Rhythm Society, Association, St Davids, Arrhythmia, Medical Center, Medical device

AUSTIN, Texas, Oct. 26, 2022 /PRNewswire/ -- The executive medical director of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently led Venice Arrhythmias 2022, a biennial international workshop on cardiac arrhythmias held in Venice, Italy from October 13 to October 15, 2022.

Key Points: 
  • AUSTIN, Texas, Oct. 26, 2022 /PRNewswire/ -- The executive medical director of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently led Venice Arrhythmias 2022, a biennial international workshop on cardiac arrhythmias held in Venice, Italy from October 13 to October 15, 2022.
  • As Venice Arrhythmias president, Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C.,organized the programming for the event.
  • The workshop featured worldwide recognized leaders in the field of basic and clinical cardiac electrophysiology presenting the latest scientific advances and innovations.
  • Venice Arrhythmias wasestablishedin 1989, making it the longest-running and most successful electrophysiology conference in the world.

BioSig Invited to Attend and Sponsor Venice Arrhythmias 2022

Retrieved on: 
Wednesday, October 12, 2022
Physician, U.S. Securities and Exchange Commission, Mayo Clinic, SEC, PURE, Module, Science, NASDAQ, Cardiology, VeniceArrhythmias, Research, Security (finance), Atrial fibrillation, Saint David, ALFA, Cardiac electrophysiology, Electrophysiology, Risk, Journal of Cardiovascular Electrophysiology, Trial of the century, Company, Doctor of Philosophy, Industry, CEO, Cleveland Clinic, Congress, Nautilus, Inc. v. Biosig Instruments, Inc., Medical Center, GLOBE, St Davids, Journal, European, FHRS, FDA, COVID-19, Â, Leadership, Pharmaceutical industry, MD

Westport, CT, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (BioSig or the Company) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP System, today announced that it has been invited to attend the 17th Edition Venice Arrhythmias 2022 Congressa Heart Rhythm Society sponsored program taking place from October 13-15, 2022 in Venice, Italy.

Key Points: 
  • Westport, CT, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (BioSig or the Company) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP System, today announced that it has been invited to attend the 17th Edition Venice Arrhythmias 2022 Congressa Heart Rhythm Society sponsored program taking place from October 13-15, 2022 in Venice, Italy.
  • Their research is impacting technological advancement in the industry, commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.
  • Venice Arrhythmias 2022 is a world-renown congress that convenes global experts and innovators in the field of heart rhythm disorders to discuss the latest scientific advances and cutting-edge technologies in cardiac electrophysiology, pacing, and clinical arrhythmology.
  • BioSig Technologies is an advanced digital signal processing technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias.